Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Leading Stem Cell Therapy CEO to Share Vision, Challenges and Insights
  • USA - English


News provided by

Okyanos

Jun 06, 2016, 09:00 ET

Share this article

Share toX

Share this article

Share toX

Mathew Feshbach - Okyanos Cell Therapy CEO
Mathew Feshbach - Okyanos Cell Therapy CEO
Youtube
Youtube

We have dedicated ourselves to becoming leaders in cell therapy..by establishing, maintaining and evolving best practices with the unwavering goal of safely improving the quality of life for patients-- Okyanos Cell Therapy CEO - Matthew Feshbach

Post this

Freeport, Grand Bahama (PRWEB) June 06, 2016 -- Matthew Feshbach, CEO and co-founder of Okyanos Cell Therapy, will share his vision for establishing cell therapy as a worldwide standard of care for chronic, degenerative diseases at the upcoming Regenera Global Conference, “Regenerative Medicine 2.0: Redefining the Practice,” to be held in Freeport, Grand Bahama on June 23-25, 2016. Feshbach will also address some of the challenges experienced in the development and launch of Okyanos with the hope that peers may use these insights to achieve success in bringing safe, beneficial adult stem cell therapies to chronically ill patients.

It was the 2011 Cell Society meeting which served as a catalyst for Feshbach’s interest in stem and regenerative cell therapy. After speaking to the presenters and key opinion leaders in attendance, he saw cell therapy was the next phase in the evolution of medicine.

“The Cell Society meeting was an initial impetus for the creation of Okyanos. It was a very well-planned meeting with a rich agenda, and I became fascinated with the science and reparative mechanisms of the human body,” says Feshbach. “However, I could see from the experts’ data that establishing a true standard of care for stem cell therapy wouldn’t be as simple as purchasing a centrifuge and enzymes. I turned to these same experts as we embarked on a plan for building a cell therapy center of excellence.”

Okyanos Cell Therapy was officially founded in August, 2011 and began treating patients in 2014. Although the founders underestimated what it would take to build a world-class facility and make this new standard of care available to patients, co-founder and now CEO Matthew Feshbach says he wouldn’t have done anything differently to speed up the process.

“From the outset, we have dedicated ourselves to becoming leaders in cell therapy, but leadership in a market with the enormous potential of adult stem cell therapy is something that is hard won,” adds Feshbach. “We won’t be a leader by being a better competitor, but by establishing, maintaining and evolving best practices with the unwavering goal of safely improving the quality of life for patients. Had we cut corners and opted to save time or resources in the creation of Okyanos, we would not be seeing the results we have achieved in our patients’ outcomes.”

The vast number of patients who potentially stand to benefit from the reparative mechanisms of autologous (patients’ own) stem cells is contrasted by a variety of challenges in translating and commercializing cell-based therapies—not the least of which is insufficient global regulation and standards for patient safety.

Okyanos’ founders chose The Bahamas as the surgical center’s location for its pristine beauty and close proximity to the United States, but more importantly the country established legislation in 2013 which would tightly regulate stem cell research and therapy.

Dr. Glen Beneby, Chief Medical Officer for the Commonwealth of The Bahamas, leads the National Stem Cell Ethics Committee (NSCEC) and maintains a focus on ethical, safe industry development for stem cell therapy in The Bahamas.

“Public safety is paramount, and Okyanos has been aligned with the NSCEC on this from the beginning,” said Dr. Beneby. “We put forth significant effort early on to appoint highly qualified members of our committee to ensure rigorous oversight and to reject those persons and facilities which could endanger patients or the reputation of our jurisdiction.”

Dr. Beneby will also address the conference as a panelist in the “Advancing Stem Cell Therapy Regulations in the Bahamas” discussion.

The Regenera Global meeting will offer perspectives on some of the most current regenerative medicine knowledge in both research and clinical applications and will feature prominent physicians including the Mayo Clinic’s Thomas A. Gonwa, MD, as well as the Director of Regenerative Medicine Research at Texas Heart Institute, Doris Taylor, PhD.

To learn more about Regenera Global or to register for this conference, please visit http://www.regeneraglobal.com.

Those interested in learning more about cell therapy at Okyanos can do so by calling 1-855-659-2667 or by visiting http://www.okyanos.com.

ABOUT OKYANOS CELL THERAPY: (OH – KEY – AH – NOS)
Based in Freeport, Grand Bahama, Okyanos brings a new standard of care and a better quality of life to patients with chronic, degenerative conditions. Okyanos Cell Therapy utilizes a unique blend of stem and regenerative cells derived from patients’ own adipose (fat) tissue which helps improve blood flow, modulate destructive immune response and prevent further cell death. Okyanos is fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards. The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow.

ABOUT REGENERA GLOBAL, INC.:
Based in Puerto Rico, Regenera Global, Inc. is a bio-technology firm focused on developing and commercializing innovative therapies, providing consulting services and educational events to physicians and healthcare practitioners to expand their knowledge of regenerative medicine clinical applications which may include, but is not limited to, stem cell and gene therapy, tissue engineering, and select medical devices. Regenera Global is working to bridge the gap of access to regenerative medicine between the progress made through research and what is available clinically to physicians and patients.

Corina Froese, Okyanos, http://www.okyanos.com, +1 727-290-4780, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.